Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma
Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma. Prospective Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Caba, Argentina
- Hospital Italiano de Buenos Aires
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults between 50 and 75 years with a defined complete rotator cuff tear as compatible clinical and confirmation by magnetic resonance imaging (MRI).
- Minimum of 3 months of failed conservative treatment (anti-inflammatory, physical therapy and infiltration with corticosteroids)
Exclusion Criteria:
- Refusal to participate or informed consent,
- Revision surgery,
- Partial repair,
- Patients with shoulder osteoarthritis> 2
- Advanced fat infiltration of the rotator cuff muscles (STAGE 3 or 4)
- Systemic or rheumatoid arthritis,
- Uncontrolled diabetes, (patients for whom surgery is contraindicated in the preoperative evaluation by the clinician and anesthesiologist)
- Acute or chronic infections of the shoulder to be operated on
- Ongoing cancer chemotherapy therapies
- Sepsis, septic arthritis, osteomyelitis or other ongoing infectious processes;
- Previous operations on the affected shoulder,
- Patients with autoimmune diseases;
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arthroscopic rotator cuff repair and platelet rich plasma
A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
|
A double-row rotator cuff repair will be performed.
A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
|
|
Active Comparator: Arthroscopic rotator cuff repair
A standard double-row arthroscopic rotator cuff repair will be performed.
|
A double-row rotator cuff repair will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of re-tear rates between groups.
Time Frame: 6 months
|
Postoperative MRI to assess the structural integrity of the repaired rotator cuff.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From baseline in shoulder functional scores at 3, 6 and 12 months
Time Frame: baseline, 3, 6, and 12 months
|
The ASES score (American Shoulder and Elbow Surgeons) and the Constant score will be used.
Both scores assess the general function of the shoulder in different activities of daily life, global mobility of the shoulder and pain with usual tasks.
They are scores ranging from 0 to 100.
Both scores are validated and are the reference scores for clinical research on rotator cuff pathology
|
baseline, 3, 6, and 12 months
|
|
Change From baseline in pain at 3, 6 and 12 months
Time Frame: baseline, 3, 6, and 12 months
|
The visual analog scale (VAS) will be used to assess the level of pain during activities of daily living.
0 will be considered as "no pain" and 10 as "the worst pain of his life."
|
baseline, 3, 6, and 12 months
|
|
Number of Participants With Treatment-Related Adverse Events
Time Frame: 3, 6, and 12 months
|
Adverse effects and postoperative complications will be recorded.
|
3, 6, and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Luciano Rossi, MD, Hospital Italiano de Buenos Aires
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5702
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.